Результаты поиска

Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis.

As indicators of responsiveness to a tumour necrosis factor (TNF)alpha blocking agent (infliximab) are lacking in rheumatoid arthritis, we have used gene profiling in peripheral blood mononuclear cells to predict a good versus poor response to infliximab. Thirty three patients with very active disease (Disease Activity Score 28 >5.1) that resisted weekly methotrexate therapy were given infliximab at baseline, weeks 2 and 6, and every 8th week thereafter. The patients were categorized as responders if a change of Disease Activity Score 28 = 1.2 was obtained at 3 months. Mononuclear cell RNAs we…

Pulmonary infectious complications associated with anti-TNFalpha therapy (infliximab) for rheumatoid arthritis.

Two patients with rheumatoid arthritis (RA) that developed serious infectious complications following anti-TNFalpha therapy (infliximab) are reported. Patient 1 developed tuberculosis with high fever, refractory diarrhea and mediastinal lymphadenopathy. Trans-bronchial needle biopsy was useful to confirm the diagnosis. Patient 2 showed sudden onset of dyspnea with diffuse bilateral lung infiltration caused by pneumocystis jiroveci pneumonia and the diagnosis was confirmed by broncho-alveolar lavage. Physicians should be alerted to infectious complications with atypical presentation and rapid p…

Tumor necrosis factor-alpha monoclonal antibody, infliximab, used to manage severe sciatica.

STUDY DESIGN: An open-label study was conducted. OBJECTIVE: To evaluate the efficacy and safety of infliximab, a monoclonal chimeric antibody, against tumor necrosis factor-alpha (TNFalpha) for the treatment of severe sciatica. SUMMARY OF BACKGROUND DATA: Evidence from animal studies indicates that TNFalpha plays a role in the pathophysiology of sciatica. Anti-TNFalpha therapy has not been previously evaluated in sciatic patients. METHODS: In this study, 10 patients with disc herniation-induced severe sciatica received infliximab (Remicade 3 mg/kg) intravenously over 2 hours. The outcome wa…

Corticosteroid-resistant pyoderma gangrenosum associated with Crohn's disease: rapid cure with infliximab.

A 41-year-old woman with Crohn's disease had a severe and rapidly extensive corticosteroid-resistant pyoderma gangrenosum (PG) of the leg. She had been treated 2 years previously with antibiotics and surgery for a similar lesion of the back of the hand which had been diagnosed as a fulminating infection. Infliximab 5 mg/kg was given at weeks 0, 5 and 9. A dramatic response was observed within 72 h with a favourable effect persisting for 4 weeks after each infliximab infusion. A complete healing was achieved at week 11. This case illustrates that (1). PG of the hand is frequently misdiagnosed a…

A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy.

OBJECTIVES: To compare the efficacy, safety, immunogenicity and pharmacokinetics (PK) of SB2 to the infliximab reference product (INF) in patients with moderate to severe rheumatoid arthritis (RA) despite methotrexate therapy. METHODS: This is a phase III, randomised, double-blind, multinational, multicentre parallel group study. Patients with moderate to severe RA despite methotrexate therapy were randomised in a 1:1 ratio to receive either SB2 or INF of 3 mg/kg. The primary end point was the American College of Rheumatology 20% (ACR20) response at week 30. Inclusion of the 95% CI of the ACR…

Трубоактивное демиелионирование, вызванное Infliximab в пациенте с руматоидным артритом: доклад по делу.

Для лечения ревматоидного артрита (RA), псориатического и анкилосирующего артрита и воспалительного кишечника успешно использовались ингибиторы (TNF-α). Хотя эти ингибиторы эффективно сокращают подстрекательскую активность иммунных расстройств, они связаны с центральной нервной системой (СНС) и периферийным демиэлированием. В этом исследовании сообщается о 44-летней пациентке РН, у которой появились неврологические симптомы после прохождения инфликсимаб-терапии из-за вытяжных демиелионирующих повреждений. Изображение выводов привело к прекращению употребления наркотиков и лечения кортикостерои

Совпадение в аннотации оригинала
Tumor Necrosis Factor-alpha (TNF-α) inhibitors have been successfully used to treat rheumatoid arthritis (RA), psoriatic and ankylosing arth … e report a 44-year-old female patient with RA who developed neurological symptoms after a course of infliximab therapy due to tumefactive demyelinating lesions (TDLs). Imaging findings led to discontinuation of the drug and treatment with corticosteroids, resulting in clinical improvement. This case underscores the importance of monitoring neurological side …

Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data.

OBJECTIVE: To gain clinical experience on the effectiveness and safety of switching from infliximab-Remicade(INX) to infliximab-biosimilar-CT-P13(INB) in patients with established rheumatic disease. METHODS: Patients receiving INX treatment at a rheumatology clinic consented to switching from INX to INB. Patient reported outcomes (PROs), disease-activity, and inflammatory markers were recorded at every visit. Generalized estimating equation models and time-dependent area under the curve (AUC) before/during INX and INB treatments were employed. RESULTS: Thirty-nine consecutive patients [mean …

Subcutaneous infliximab in inflammatory bowel disease: bridging the gap between theory and practice.

BACKGROUND: At the end of the past century, infliximab (IFX), the first-in-class biological therapy approved in inflammatory bowel disease (IBD), dramatically modified the therapeutic armamentarium. The recent development of subcutaneous (SC) formulations of IFX offers a promising alternative, with the potential to improve patient convenience, adherence, and overall outcomes. This review explores the clinical evidence supporting the initiation of SC IFX and the transition from intravenous (IV) to SC IFX. METHODS: Comprehensive review using MEDLINE (source PUBMED). RESULTS: Comparative studie…

Infliximab originator and biosimilars have similar efficacy in children with inflammatory bowel disease.

OBJECTIVES: To evaluate whether children with inflammatory bowel disease (IBD) who initiate infliximab originator versus biosimilar experience similar clinical outcomes at 12 months. METHODS: We conducted a retrospective cohort study evaluating prospectively collected data from the ImproveCareNow (ICN) Network registry. Children <18 years old initiating infliximab originator or biosimilar between January 2016 and September 2022 were eligible. Matched groups initiating originator and biosimilar were created with propensity score matching based on age at initiation, sex, race, year therapy init…

Second-line infliximab therapy for ulcerative colitis (SLIT-UC): a retrospective cohort study.

BACKGROUND: Infliximab's efficacy as a second-line agent in moderate or severe ulcerative colitis after prior advanced therapy failure is unclear. Registration trials for infliximab did not assess its efficacy after exposure to other advanced therapies, a sequence in which it is increasingly used. We evaluate infliximab's second-line effectiveness, identify predictors of response, and compare outcomes to its first-line use. METHODS: We conducted a retrospective cohort study of adults with ulcerative colitis treated with infliximab at a tertiary care center. Patients were categorized by line o…

[Infliximab-induced autoimmune-like hepatitis developed during treatment for Crohn's disease:a case report].

A female patient in her 20s with abdominal pain, diarrhea, fever, and arthralgia was referred to our hospital. Colonoscopy revealed multiple ulcers in the right colon, and biopsy demonstrated non-caseating granulomas, leading to a Crohn's disease diagnosis. She initially received adalimumab, but secondary loss of response occurred after 5 years. Her treatment was then switched to infliximab (IFX), which induced remission. Liver dysfunction was noted at 9 months after IFX initiation. Laboratory tests revealed positive antinuclear antibody (ANA), and liver biopsy demonstrated lymphoplasmacytic i…

Risk of Infections With Infliximab vs Adalimumab Among Children With Inflammatory Bowel Disease.

IMPORTANCE: Infliximab and adalimumab are the only biologics approved by the US Food and Drug Administration for use in children with inflammatory bowel disease (IBD). The comparative infection risks between infliximab and adalimumab have not been evaluated in clinical settings. OBJECTIVE: To compare the risk of infections with infliximab vs adalimumab among pediatric patients with IBD using nationwide claims data. DESIGN, SETTING, AND PARTICIPANTS: This cohort study used data from 2 nationwide health care claims databases from January 1, 2016, to February 28, 2025. The study included childr…

Infliximab-induced Remission of Postoperative Pyoderma Gangrenosum: A Case Report and Literature Review.

BACKGROUND: Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis characterized by painful, rapidly progressive cutaneous ulcers. Post … ade, and systemic corticosteroid therapy was initiated, resulting in partial improvement. RESULTS: Infliximab was prescribed, leading to complete healing, and all immunosuppressive agents were discontinued, with the patient remaining in remission. This case highlights the importance of recognizing PPG in postsurgical ulcers that fail to respond to conventio …

Effects of infliximab, an anti-TNF-α, on cyclophosphamide-induced bone marrow toxicity.

PURPOSE: Cyclophosphamide is a widely used anticancer agent, though its clinical application is often constrained by myelotoxicity. Infliximab, a monoclonal antibody targeting TNF-α, may alleviate this toxicity by mitigating oxidative stress. This study aimed to assess the protective effects of infliximab against cyclophosphamide-induced myelotoxicity, focusing on bone marrow and spleen-related parameters. METHODS: Male Wistar rats (260 ± 20 g) were randomly divided into four groups (n = 5 each): Control (normal saline), Infliximab (7 mg/kg, IP), Cyclophosphamide (200 mg/kg, IP), and Inflixim…

Varicella Development after Infliximab Therapy for Refractory Pouchitis in Post-surgical Ulcerative Colitis.

A boy in his late teens had undergone proctocolectomy for refractory ulcerative colitis eight months ago. Two months earlier, he had developed pouchitis and received intensive treatment with infliximab (IFX). Two days after the IFX injection, a fever and generalized rash appeared. Varicella zoster virus (VZV) antigen positivity in the blisters led to a diagnosis of varicella. Based on the history of VZV vaccination, environmental conditions, and VZV antibody titers in the early stages of the disease, VZV reactivation was suggested. The possibility of varicella should be considered when blister…